Objetivo de la investigación Los objetivos de la investigación son identificar los genes causales de la toxicidad mitocondrial y la neurodegeneración inducidas por la quimioterapia en las neuronas ...

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.

The statewide network is designed to overcome manufacturing bottlenecks that have delayed or stalled development and approval of regenerative medicines. “These awards are a critical first step in ...

Title 17 California Code of Regulations Section 100080(f) designates all human pluripotent stem cell lines derived in accordance with the CIRM regulations as “acceptably derived.” These cell lines may ...

Jonathan Thomas, PhD, JD, is President and CEO of the California Institute for Regenerative Medicine (CIRM). Thomas was previously the Chair of the CIRM governing Board from June 2011 to March 2023.

Joseph Panetta is President & CEO and a member of the Board of Directors of Biocom California, the state association that advocates for 1800 companies, service sector firms, universities, and research ...

Anne-Marrie Duliege, MD, is a Senior Executive and Chief Medical Officer with 30 years of experience guiding biopharmaceutical companies through development and commercial stages. Dr. Duliege is ...

San Francisco, CA – California’s stem cell agency, the California Institute for Regenerative Medicine (CIRM) today approved $150 million in new funding to help move promising stem cell-based therapies ...

It takes a lot of effort to develop a promising stem cell research idea into an effective treatment that can help patients. CIRM funds a pipeline of projects spanning discovery, translation and ...

Currently, CIRM is not accepting new applications for any existing Clinical (CLIN), Translational (TRAN), Education (EDUC), or Infrastructure (INFR) opportunities. However, CIRM will accept ...